6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Expression profiles of p53/p73, NME and GLI families in metastatic melanoma tissue and cell lines

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Unlike other tumours, TP53 is rarely mutated in melanoma; however, it fails to function as a tumour suppressor. We assume that its functions might be altered through interactions with several families of proteins, including p53/p73, NME and GLI. To elucidate the potential interplay among these families we analysed the expression profiles of aforementioned genes and proteins in a panel of melanoma cell lines, metastatic melanoma specimens and healthy corresponding tissue. Using qPCR a higher level of NME1 gene expression and lower levels of Δ40p53β, ΔNp73, GLI1, GLI2 and PTCH1 were observed in tumour samples compared to healthy tissue. Protein expression of Δ133p53α, Δ160p53α and ΔNp73α isoforms, NME1 and NME2, and N′ΔGLI1, GLI1FL, GLI2ΔN isoforms was elevated in tumour tissue, whereas ∆Np73β was downregulated. The results in melanoma cell lines, in general, support these findings. In addition, we correlated expression profiles with clinical features and outcome. Higher Δ133p53β and p53α mRNA and both GLI1 mRNA and GLI3R protein expression had a negative impact on the overall survival. Shorter overall survival was also connected with lower p53β and NME1 gene expression levels. In conclusion, all examined genes may have implications in melanoma development and functional inactivity of TP53.

          Related collections

          Most cited references56

          • Record: found
          • Abstract: found
          • Article: not found

          p53 isoforms can regulate p53 transcriptional activity.

          The recently discovered p53-related genes, p73 and p63, express multiple splice variants and N-terminally truncated forms initiated from an alternative promoter in intron 3. To date, no alternative promoter and multiple splice variants have been described for the p53 gene. In this study, we show that p53 has a gene structure similar to the p73 and p63 genes. The human p53 gene contains an alternative promoter and transcribes multiple splice variants. We show that p53 variants are expressed in normal human tissue in a tissue-dependent manner. We determine that the alternative promoter is conserved through evolution from Drosophila to man, suggesting that the p53 family gene structure plays an essential role in the multiple activities of the p53 family members. Consistent with this hypothesis, p53 variants are differentially expressed in human breast tumors compared with normal breast tissue. We establish that p53beta can bind differentially to promoters and can enhance p53 target gene expression in a promoter-dependent manner, while Delta133p53 is dominant-negative toward full-length p53, inhibiting p53-mediated apoptosis. The differential expression of the p53 isoforms in human tumors may explain the difficulties in linking p53 status to the biological properties and drug sensitivity of human cancer.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress.

            p63, p73 and p53 compose a family of transcription factors involved in cell response to stress and development. p53 is the most frequently mutated gene in cancer (50%) and loss of p53 activity is considered to be ubiquitous to all cancers. Recent publications may have a profound impact on our understanding of p53 tumour suppressor activity. p63, p73 and p53 genes have a dual gene structure conserved in drosophila, zebrafish and man. They encode for multiple p63, p73 or p53 proteins containing different protein domains (isoforms) due to multiple splicing, alternative promoter and alternative initiation of translation. In this review, we describe the different isoforms of p63, p73, p53 and their roles in development and cancer. The changes in the interactions between p53, p63 and p73 isoforms are likely to be fundamental to our understanding in the transition between normal cell cycling and the onset of tumour formation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              p63 and p73: roles in development and tumor formation.

              The tumor suppressor p53 is critically important in the cellular damage response and is the founding member of a family of proteins. All three genes regulate cell cycle and apoptosis after DNA damage. However, despite a remarkable structural and partly functional similarity among p53, p63, and p73, mouse knockout studies revealed an unexpected functional diversity among them. p63 and p73 knockouts exhibit severe developmental abnormalities but no increased cancer susceptibility, whereas this picture is reversed for p53 knockouts. Neither p63 nor p73 is the target of inactivating mutations in human cancers. Genomic organization is more complex in p63 and p73, largely the result of an alternative internal promoter generating NH2-terminally deleted dominant-negative proteins that engage in inhibitory circuits within the family. Deregulated dominant-negative p73 isoforms might play an active oncogenic role in some human cancers. Moreover, COOH-terminal extensions specific for p63 and p73 enable further unique protein-protein interactions with regulatory pathways involved in development, differentiation, proliferation, and damage response. Thus, p53 family proteins take on functions within a wide biological spectrum stretching from development (p63 and p73), DNA damage response via apoptosis and cell cycle arrest (p53, TAp63, and TAp73), chemosensitivity of tumors (p53 and TAp73), and immortalization and oncogenesis (DeltaNp73).
                Bookmark

                Author and article information

                Contributors
                slade@irb.hr
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                28 August 2019
                28 August 2019
                2019
                : 9
                : 12470
                Affiliations
                [1 ]ISNI 0000 0004 0635 7705, GRID grid.4905.8, Division of Molecular Medicine, , Ruđer Bošković Institute, ; Bijenička cesta 54, HR-10000 Zagreb, Croatia
                [2 ]ISNI 0000 0004 1937 0351, GRID grid.11696.39, Department of Cellular, , Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, ; Povo (Trento), IT-38123 Italy
                [3 ]ISNI 0000 0000 9336 4196, GRID grid.412488.3, Sestre milosrdnice University Hospital Center, Vinogradska cesta 29, ; HR-10000 Zagreb, Croatia
                Author information
                http://orcid.org/0000-0001-9757-6636
                http://orcid.org/0000-0001-9927-3727
                http://orcid.org/0000-0001-9231-379X
                http://orcid.org/0000-0003-3620-3099
                Article
                48882
                10.1038/s41598-019-48882-y
                6713730
                31462745
                26055b2d-8ee9-4db9-ad14-2cd149b3cb87
                © The Author(s) 2019

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 4 April 2019
                : 1 August 2019
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100004488, Hrvatska Zaklada za Znanost (Croatian Science Foundation);
                Award ID: IP-11-2013-1615
                Award ID: IP-11-2013-1615
                Award ID: IP-11-2013-1615
                Award ID: IP-11-2013-1615
                Award ID: IP-11-2013-1615
                Award ID: IP-11-2013-1615
                Award ID: IP-11-2013-1615
                Award ID: IP-11-2013-1615
                Award ID: IP-11-2013-1615
                Award ID: IP-11-2013-1615
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s) 2019

                Uncategorized
                melanoma,molecular medicine
                Uncategorized
                melanoma, molecular medicine

                Comments

                Comment on this article